Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study

doi:10.4239/wjd.v4.i1.8

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6583)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

385

HTML

3765

Tables (1-1)

230

Sum=4380

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1123

Download

1080

Sum=2203

Feb 15, 2013 (publication date) through Jan 12, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Diabetes. Feb 15, 2013; 4(1): 8-13
Published online Feb 15, 2013. doi: 10.4239/wjd.v4.i1.8

Table 1 Baseline patient profile and post-treatment data

	Sitagliptin group		Nateglinide group
	Before treatment	After 3 mo of treatment	Before treatment	After 3 mo of treatment
Age (yr)	63.85 ± 12.92	-	66.44 ± 9.02	-
Sex: M/F (n)	15/5	15/5	12/4	12/4
Body weight (kg)	68.79 ± 12.89¹	69.30 ± 13.18	58.36 ± 8.54	58.75 ± 8.52
Systolic blood pressure (mmHg)	134.3 ± 19.3	126.5 ± 11.1	129.1 ± 13.9	122.7 ± 14.8
Diastolic blood pressure (mmHg)	81.5 ± 12.9	73.3 ± 7.4^b	76.9 ± 8.8	74.3 ± 10.2
HbA_1c (%)	7.2 ± 0.7	7.0 ± 0.8^b	7.2 ± 0.4	6.8 ± 0.5^b
Glycated albumin (%)	19.3 ± 3.6	17.7 ± 2.6^b	19.9 ± 3.4	18.1 ± 2.8^b
1.5-AG (μmol/L)	65.5 ± 45.8	81.6 ± 46.2^b	51.0 ± 22.7	69.5 ± 29.3^b
Fasting blood glucose (mmol/L)	7.8 ± 1.7	7.3 ± 1.6	8.1 ± 1.0	7.6 ± 1.5
Blood glucose 1 h postprandially (mmol/L)	12.0 ± 3.0	10.6 ± 3.1^b	13.6 ± 2.3	11.0 ± 2.8^b
Blood glucose 3 h postprandially (mmol/L)	7.6 ± 2.5	6.6 ± 2.0^b	7.6 ± 2.5	6.5 ± 1.9^a
Apo-B48 AUC (g/L per hour)	2.48 ± 0.11	1.94 ± 0.78^a	3.14 ± 0.29	2.29 ± 0.16
Apo-A1 AUC (g/L per hour)	4.64 ± 0.73	4.50 ± 0.76	4.59 ± 0.73	4.67 ± 0.76
Apo-B AUC (g/L per hour)	2.73 ± 0.47	2.91 ± 0.46	2.60 ± 0.46	2.64 ± 0.40
Apo-C3 AUC (g/L per hour)	0.30 ± 0.07	0.28 ± 0.06	0.31 ± 0.11	0.28 ± 0.09
Fasting insulin (pmol/L)	53.3 ± 26.9	58.4 ± 34.4	41.3 ± 29.0	40.4 ± 31.5
Insulin 1 h postprandially (μU/mL)	279.3 ± 115.7	275.1 ± 143.4	230.1 ± 104.2	248.7 ± 112.2
Fasting glucagon (ng/L)	67.2 ± 15.9	66.6 ± 16.0	65.1 ± 16.4	70.1 ± 16.0
Glucagon 1 h postprandially (ng/L)	80.3 ± 17.0	70.3 ± 16.9^a	79.0 ± 13.4	81.5 ± 20.6
Fasting triglycerides (mmol/L)	1.26 ± 0.81	1.09 ± 0.61^a	1.54 ± 1.44	1.11 ± 0.60

¹This parameter showed a significant between-group difference (P < 0.05) before treatment. Data are shown as the mean ± SD (^aP < 0.05,

^bP < 0.01 vs time curve). Area under the concentration vs time curve (AUC) data were obtained from before to three hours after the test meal. The t test was used for statistical analysis. M: Male; F: Female; 1.5-AG: 1.5-anhydroglucitol; Apo: Apolipoprotein; HbA_1c: Hemoglobin A_1c.

Citation: Kojima Y, Kaga H, Hayashi S, Kitazawa T, Iimura Y, Ohno M, Yoshitsugu M, Fujiwara M, Hiyoshi T. Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study. World J Diabetes 2013; 4(1): 8-13
URL: https://www.wjgnet.com/1948-9358/full/v4/i1/8.htm
DOI: https://dx.doi.org/10.4239/wjd.v4.i1.8